glp 1 vs wegovy vs. Ozempic: What To Know Wegovy vs. Ozempic: Important Differences

2017, doi: 10.1111/dom.12977

PubMed, Saleh, Rofida A., et al

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown promising effects on heart failure (HF) outcomes, particularly in phenotype-specific populations

According to the American Diabetes Association (ADA) Standards of Care, GLP-1 receptor agonists with proven cardiovascular benefit are recommended for many patients with type 2 diabetes who have established cardiovascular disease, with individualized therapy based on patient factors

The Evidence Multiple large cardiovascular outcome trials have demonstrated GLP-1 medications reduce heart attacks, strokes, and cardiovascular death: SUSTAIN-6 (semaglutide): 26% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk

Through online consultations, licensed healthcare providers can evaluate your health, discuss your weight loss goals, and prescribe medications if you qualify